TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05735951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STIRIPENTOL oral administration
Description: Oral administration of:~* Days 1 and 2: 1000 mg of stiripentol (single dose at the end of breakfast),~* Day 3 to Day 14: 1000 mg of stiripentol bis in die (BID) (approximately 12 hours apart, at the end of breakfast and at the end of dinner),~* Day 15: 1000 mg of stiripentol (single dose at the end of breakfast).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STIRIPENTOL oral administration
Description: Oral administration of:~* Days 1 and 2: 1000 mg of stiripentol (single dose at the end of breakfast),~* Day 3 to Day 14: 1000 mg of stiripentol bis in die (BID) (approximately 12 hours apart, at the end of breakfast and at the end of dinner),~* Day 15: 1000 mg of stiripentol (single dose at the end of breakfast).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STIRIPENTOL oral administration
Description: Oral administration of:~* Days 1 and 2: 1000 mg of stiripentol (single dose at the end of breakfast),~* Day 3 to Day 14: 1000 mg of stiripentol bis in die (BID) (approximately 12 hours apart, at the end of breakfast and at the end of dinner),~* Day 15: 1000 mg of stiripentol (single dose at the end of breakfast).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STIRIPENTOL oral administration
Description: Oral administration of:~* Days 1 and 2: 1000 mg of stiripentol (single dose at the end of breakfast),~* Day 3 to Day 14: 1000 mg of stiripentol bis in die (BID) (approximately 12 hours apart, at the end of breakfast and at the end of dinner),~* Day 15: 1000 mg of stiripentol (single dose at the end of breakfast).
Study: NCT06482372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: repetitive transcranial magnetic stimulation at both cerebral hemisphere

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: repetitive transcranial magnetic stimulation at both cerebral hemisphere

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: repetitive transcranial magnetic stimulation at both cerebral hemisphere
Study: NCT05810987

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RESTORE
Description: Virtual educational curriculum organized into the following modules:~Module Specific Communication Strategies~1. Introduction~2. Preparing for and introducing a conversation \[Consider personal bias /Building rapport /Ask permission\]~3. Assessing understanding \[Avoid correcting /Open ended questions\]~4. Giving information \[Give a warning shot /Using silence /Wish/worry/wonder\]~5. Explore goals \[Reflective listening /Naming, validating emotion~6. Summarizing and recommending a plan \[Values-based recommendation /Aligning with goals /REMAP (Reframe, Expect emotion, Map goals, Align, Propose plan)\]

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RESTORE
Description: Virtual educational curriculum organized into the following modules:~Module Specific Communication Strategies~1. Introduction~2. Preparing for and introducing a conversation \[Consider personal bias /Building rapport /Ask permission\]~3. Assessing understanding \[Avoid correcting /Open ended questions\]~4. Giving information \[Give a warning shot /Using silence /Wish/worry/wonder\]~5. Explore goals \[Reflective listening /Naming, validating emotion~6. Summarizing and recommending a plan \[Values-based recommendation /Aligning with goals /REMAP (Reframe, Expect emotion, Map goals, Align, Propose plan)\]

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Interaction and Coaching
Description: Skills sessions with standardized patients (SPs) along with coaching feedback.
Study: NCT05906056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM)
Description: CPM uses machines to move a joint passively i.e. without the patient exerting any effort. A motorized device moves the joint repetitively to a set of degrees and movement speed, determined by the caregiver either a medical doctor (physiatrist or orthopedic surgeon) or a physiotherapist. Its action preserves the joint's range of motion (ROM)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy (PT)
Description: Daily passive range of motion exercises (ROM) performed by the physiotherapist of the intensive care unit (ICU)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy (PT)
Description: Daily passive range of motion exercises (ROM) performed by the physiotherapist of the intensive care unit (ICU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid Injection
Description: one dose of intravenous zoledronic acid will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid Injection
Description: one dose of intravenous zoledronic acid will be administered
Study: NCT06379321

Intervention type: DEVICE
Intervention: Triathlon Hinge Knee (THK) System
Description: Participants receive Triathlon Hinge Knee (THK) System during primary or revision knee arthroplasty in accordance with the indications for use

Intervention type: DEVICE
Intervention: Triathlon Hinge Knee (THK) System
Description: Participants receive Triathlon Hinge Knee (THK) System during primary or revision knee arthroplasty in accordance with the indications for use

Intervention type: DEVICE
Intervention: Triathlon Hinge Knee (THK) System
Description: Participants receive Triathlon Hinge Knee (THK) System during primary or revision knee arthroplasty in accordance with the indications for use
Study: NCT04539002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise performed on a stationary ergometer for 30 minutes, thrice weekly, with graded supervision. Participants will participate in the intervention over 24 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Group Control
Description: A monthly, hour-long, class over various MS topics and symptoms, led by a trained facilitator.
Study: NCT05962177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood withdrawal
Description: Blood withdrawal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood withdrawal
Description: Blood withdrawal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood withdrawal
Description: Blood withdrawal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: Neuropsychological tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: Neuropsychological tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: Neuropsychological tests
Study: NCT05364099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution
Description: 2.5 ml of 1% Lidocaine will be administered via injection in suprascapular nerve in the suprascapular notch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Injection
Description: 0.5 ml 40mg/ml Triamcinolone will be administered via injection in suprascapular nerve in the suprascapular notch

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular Nerve Block
Description: This procedure involves injection of a lidocaine and triamcinolone mixture into the suprascapular nerve in the suprascapular notch using ultrasound guidance for proper placement of drugs.
Study: NCT05752305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 Mg/mL Injectable Solution
Description: Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MethylPREDNISolone 40 Mg/mL Injectable Suspension
Description: Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
Study: NCT05062109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal geriatric prehabilitation
Description: Multimodal prehabilitation will be carried out over a period of 6 weeks in a day admission (once a week) and at home, and will include:~* Muscle rehabilitation developed with a physiotherapist or physical activity monitor~* Nutritional support (dietitian at the 1st, 3rd, and 6th day admission (DA))~* Cognitive and physical stimulation Exergame~* Psychological support by a psychologist~* Information in the form of videos on the main risks and important points to know and prepare before and after surgery~* Assessment of patient satisfaction, any limitations encountered, the possible performance of exercises at home and the occurrence of any adverse effects.~* One session of adapted physical activity at home of one hour per week by a physical trainer from the Siel Bleu association
Study: NCT06379321

Intervention type: DEVICE
Intervention: Triathlon Hinge Knee (THK) System
Description: Participants receive Triathlon Hinge Knee (THK) System during primary or revision knee arthroplasty in accordance with the indications for use
Study: NCT05883813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sustained natural apophyseal glides (SNAGS)
Description: SNAGS will be given with patient in sitting position and the therapist will be standing behind the patient. The therapist will place the thumb on the spinous process of the vertebra. Move spinous process upward towards the eyeball direction \& maintain the glide and ask the patient to turn (rotation) his head slowly in painful direction, sustain the mobilization until head turn to the midline. Three repetitions of each glide will be given and each glide will be maintained for 10 seconds at end range.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suboccipital muscle release
Description: Sub-occipital muscle release will be applied with the patient in the supine position with the eyes closed and the physiotherapist's hands placed under the patient's head, in contact with the sub-occipital muscles. The physiotherapist progressively increased the pressure exerted during the 10 minutes of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suboccipital muscle release
Description: Sub-occipital muscle release will be applied with the patient in the supine position with the eyes closed and the physiotherapist's hands placed under the patient's head, in contact with the sub-occipital muscles. The physiotherapist progressively increased the pressure exerted during the 10 minutes of treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental therapy
Description: General warm-up exercises, TENS, hot pack, trapezius stretching

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supplemental therapy
Description: General warm-up exercises, TENS, hot pack, trapezius stretching
Study: NCT05041673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Antidiabetic drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Antidiabetic drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Antidiabetic drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Antidiabetic drugs
Study: NCT06340451

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iovera° system
Description: subjects will receive ultrasound-guided iovera° system treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham iovera° system treatment
Description: subjects will receive ultrasound-guided iovera° sham system treatment
Study: NCT05132361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SELUTION SLR™ 018 DEB
Description: a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain (Uncoated) Balloon Angioplasty (PTA)
Description: a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
Study: NCT06379321

Intervention type: DEVICE
Intervention: Triathlon Hinge Knee (THK) System
Description: Participants receive Triathlon Hinge Knee (THK) System during primary or revision knee arthroplasty in accordance with the indications for use

Intervention type: DEVICE
Intervention: Triathlon Hinge Knee (THK) System
Description: Participants receive Triathlon Hinge Knee (THK) System during primary or revision knee arthroplasty in accordance with the indications for use
Study: NCT05939349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Produce Prescription Group
Description: Participants will receive vouchers equal to $40/household/month, with an additional $5/month per additional household member, for the purchase of fresh fruits and vegetables during the six-month intervention period. The vouchers will be administered in the form of a restricted Mastercard debit card.~A variety of nutrition education options will be offered throughout the intervention period and participation will be tracked. The Nutrition education options will include a periodic newsletter to participants that will include nutrition and diabetes prevention and management opportunities available through Griffin Hospital Population Health Team, the local health department, program and education opportunities available through the Registered Dietitians, local offerings by SNAP-Education and The Expanded Food and Nutrition Education Program.
Study: NCT05880771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Implant Placement
Description: Tooth extraction followed by immediate implant placement. One group will have Allograft graft in the buccal gap, the other will have Xenograft graft.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Implant Placement
Description: Tooth extraction followed by immediate implant placement. One group will have Allograft graft in the buccal gap, the other will have Xenograft graft.
Study: NCT04673305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment, Cytokine dosage
Description: Once the patient's informed consent has been acquired, a neurological examination is carried out, with functional tests required by the protocol. The patient carries out, as per clinical practice, the treatment provided for the cure of his disease. The evaluation of the tests is repeated at 6 months and 12 months after enrollment in the study. In conjunction with a venipuncture performed for the exams required by clinical management, a blood sample is taken to measure the cytokines involved in inflammatory processes.
Study: NCT05309356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACCEPT Decision Intervention
Description: The intervention consists of the CPM (ACCEPT) that is integrated with a decision aid, together called the ACCEPT Decision Intervention (ADI). The ADI will provide physicians with a quantification of the exacerbation risk for each patient and the corresponding treatment recommendation, as well as information about the benefits and risks of different inhaled therapies to discuss with the patients. The intervention also includes a 1-page take-home pamphlet on evidence-based risk behaviour factor modification for COPD, tailored to the treatment recommendation.
Study: NCT05709145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written recommendation
Description: Patients in the intervention group will receive a report of the colonoscopy that will include a written recommendation that the colonoscopy should be repeated within1 year.~The colonoscopy report will included that an adequate intestinal cleansing has not been achieved and therefore it is an invalid exploration. Additionally, a written recommendation indicating that the colonoscopy should be repeated within1 year will be included in the colonoscopy report. This recommendation is addressed both to the clinician who requested the colonoscopy and to the patient himself.
Study: NCT06166901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix IOL
Description: Trifocal IOL implanted in the capsular bag in the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism, with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix Toric IOL
Description: Toric trifocal IOL implanted in the capsular bag in the eye for the visual correction of aphakia and pre-existing corneal astigmatism in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence.
Study: NCT06242834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study: NCT05357469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate St (Scrambler Therapy)
Description: Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waitlist ST (Scrambler Therapy)
Description: Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
Study: NCT06227585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REVEAL 475 System
Description: The REVEAL 475 system will be evaluated for its ability to visualize nerve-fluorescence following bevonescein administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevonescein
Description: All patients will receive a single dose of bevonescein 500 mg via IV infusion 1-5 hours before surgery.
Study: NCT05134454

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Extended ECG investigation
Description: At least two long-term ambulatory ECG recordings with a duration of 14 days each using Philips ePatch (https://www.myheartmonitor.com/device/epatch/). The two recordings should be 2-4 months apart.
Study: NCT06205160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOFT ECoG subdural grid electrode
Description: Test Device (SOFT ECoG subdural grid electrode): used for recording. During epilepsy surgery, in addition to standard clinical protocol (recording with comparator device), subjects will undergo ≥ 2 additional intracranial recordings with the SOFT ECoG flexible high density electrode grid (TD). Recording will be registered pre- and post-resection.~All procedures will be conducted according to standard clinical practice. Any medical decision making will be done using the standard of care CE-marked device (CD). The investigational, non-CE marked device is not used for clinical decision making.
Study: NCT05203731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity exercise (typically a brisk walk or light run) will occur for 20 minutes after the emotional learning procedures on Day 1.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sitting
Description: Sitting will occur for 20 minutes after the emotional learning procedures on Day 1.
Study: NCT06218667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Dose level 1 (starting dose): 45 mg of copanlisib IV weekly x 3 weeks on/1 week off Dose level 2 (standard dose): 60 mg of copanlisib IV weekly x 3 weeks on/1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix (GnRH antagonist): 240 mg loading dose sub-cutaneous once on C1D1; 80 mg maintenance dose on C2D1 and C3D1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Standard treatment
Study: NCT06532708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5x Oxycodone Oral Tablets
Description: Participants will be prescribed 5 doses of 5mg tablets of oxycodone for postoperative pain relief.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 16x Oxycodone Oral Tablets
Description: Participants will be prescribed 16 doses of 5mg tablets of oxycodone for postoperative pain relief.
Study: NCT05937165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze-dried Blueberry Powder
Description: Three day consumption of two doses of freeze-dried blueberry powder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried Blueberry Powder
Description: Three day consumption of two doses of freeze-dried blueberry powder
Study: NCT06650059

Intervention type: OTHER
Intervention: Questionnaire
Description: Self-questionnaire intended to each patient with sickle cell disease seen in consultation in one of the three reference centers participating in the study. Patients will complete the questionnaire once, on site.